Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria

Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria

Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization....

Full description

Bibliographic Details
Main Authors: Meera Patrawala, Merin Kuruvilla, Hong Li
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Molecular Genetics and Metabolism Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2214426920300215
id doaj-31a9996f8aee49c5a6c62a3fc788f4b9
record_format Article
spelling doaj-31a9996f8aee49c5a6c62a3fc788f4b92020-11-25T02:04:06ZengElsevierMolecular Genetics and Metabolism Reports2214-42692020-06-0123Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuriaMeera Patrawala0Merin Kuruvilla1Hong Li2Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, United States of America; Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, United States of AmericaDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, United States of America; Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, United States of America; Correspondence to: M. Kuruvilla, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, United States of AmericaDepartment of Human Genetics, Emory University, School of Medicine, Atlanta, GA, United States of America; Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, United States of America; Correspondence to: H. Li, Department of Human Genetics, Emory University, School of Medicine, 1365 Clifton Rd.NE Building B #2200, Atlanta, GA 30322, United States of AmericaPegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization. A 13-step desensitization protocol was performed using three solution concentrations of Palynziq with premedication of diphenhydramine and prednisone in an outpatient setting. The patient tolerated the desensitization and was able to continue Palynziq.http://www.sciencedirect.com/science/article/pii/S2214426920300215
collection DOAJ
language English
format Article
sources DOAJ
author Meera Patrawala
Merin Kuruvilla
Hong Li
spellingShingle Meera Patrawala
Merin Kuruvilla
Hong Li
Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
Molecular Genetics and Metabolism Reports
author_facet Meera Patrawala
Merin Kuruvilla
Hong Li
author_sort Meera Patrawala
title Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_short Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_full Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_fullStr Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_full_unstemmed Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_sort successful desensitization of pegvaliase (palynziq®) in a patient with phenylketonuria
publisher Elsevier
series Molecular Genetics and Metabolism Reports
issn 2214-4269
publishDate 2020-06-01
description Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization. A 13-step desensitization protocol was performed using three solution concentrations of Palynziq with premedication of diphenhydramine and prednisone in an outpatient setting. The patient tolerated the desensitization and was able to continue Palynziq.
url http://www.sciencedirect.com/science/article/pii/S2214426920300215
work_keys_str_mv AT meerapatrawala successfuldesensitizationofpegvaliasepalynziqinapatientwithphenylketonuria
AT merinkuruvilla successfuldesensitizationofpegvaliasepalynziqinapatientwithphenylketonuria
AT hongli successfuldesensitizationofpegvaliasepalynziqinapatientwithphenylketonuria
_version_ 1724944774417350656

Similar Items